3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
157
Lung Neoplasms
73
Small Cell Lung Carcinoma
52
Neoplasms
8
Melanoma
8
Carcinoma, Renal Cell
7
Squamous Cell Carcinoma of Head and Neck
6
Mesothelioma, Malignant
6
Mesothelioma
6
Colorectal Neoplasms
6
Carcinoma
6
Breast Neoplasms
6
Stomach Neoplasms
5
Neoplasm Metastasis
5
Carcinoma, Hepatocellular
5
Triple Negative Breast Neoplasms
4
Respiratory Tract Neoplasms
4
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Neoplasms by Site
4
Uterine Cervical Neoplasms
3
Urinary Bladder Neoplasms
3
Thoracic Neoplasms
3
Respiratory Tract Diseases
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Esophageal Neoplasms
3
Carcinoma, Merkel Cell
3
Carcinoma, Bronchogenic
3
Bronchial Neoplasms
3
Adenocarcinoma of Lung
3
Interventions
Pemetrexed
6
Cisplatin
4
Carboplatin
4
pembrolizumab
3
pralsetinib
2
osimertinib
2
entinostat
2
atezolizumab
2
Paclitaxel
2
130-nm albumin-bound paclitaxel
2
trametinib
1
siltuximab
1
repotrectinib
1
ficlatuzumab
1
enzalutamide
1
durvalumab
1
dabrafenib
1
cobimetinib
1
cemiplimab
1
Vemurafenib
1
Taxes
1
Nivolumab
1
Injections
1
Gemcitabine
1
Gefitinib
1
Docetaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Histologic Type
×
durvalumab
×
Thoracic
×
Clear all
NCT06463665
2026-06-04
VIRO-25
Genelux Corporation
Phase 2
Recruiting
142 enrolled